<DOC>
	<DOC>NCT00623610</DOC>
	<brief_summary>To examine whether temporary immunosuppression with ATG, tacrolimus and MMF allows prolonged survival of beta cell allografts in type 1 diabetic patients with early chronic complications of diabetes.</brief_summary>
	<brief_title>Beta-Cell Transplantation in Pre-Uremic Patients With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<criteria>type 1 insulindependent diabetic patients in relatively good general condition nonsmoker body weight &lt; 80 kg Cpeptide &lt; 0.03 nmol/l (&lt;0.09 µg/l) 6 min. after glucagon IV (1mg) (glycemia &gt; 180 mg/dl) EBV antibody positive cooperative and reliable patient giving informed consent by signature; the patient should be informed in sufficient detail on the content and procedure of the protocol, indicating potential risks of intervention and of immunosuppressive therapy; the patient should also be informed that withdrawal of immunosuppressive therapy in patients with persistent plasma Cpeptide positivity may result in subsequent loss of ßcell graft function; the ß cell implant should be identified as a clinical trial history of thrombosis or pulmonary embolism abnormal liver function HLA antibodies</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>Diabetes mellitus, type 1</keyword>
	<keyword>pancreatic beta cell</keyword>
	<keyword>transplantation</keyword>
</DOC>